400 Oyster Point Boulevard
Suite 505
South San Francisco, CA 94080
United States
650 244 4990
https://www.titanpharm.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 4
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. David Elliot Lazar | CEO & Principal Financial Officer | 1.42M | N/A | 1991 |
Dr. Katherine L. Beebe-DeVarney Ph.D. | President, COO & Director | 462k | N/A | 1961 |
Mr. Mike Fritz | National Sales Director | N/A | N/A | N/A |
Jennifer Kiernan | Executive Assistant to CEO & Investor Communications Coordinator | N/A | N/A | N/A |
Joe Schrei | Executive Director of Commercial Operations | N/A | N/A | N/A |
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.
Titan Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.